Comparison Of Short-term Effect Of Intravitreal Ranibizumab Injection In Patients With Csme And Ncsmecoronary Syndrome

ObjectivesThe treatment methods of diabetic macular edema include retinal laser photocoagulation,intravitreal injection and combined therapy.Laser photocoagulation is the traditional treatment of diabetic macular edema,is the gold standard,but it has little effect on vision improvement.American ETDRS(1985)determined the clinical significant macular edema(CSME)is the effective type of laser treatment.This classification has been widely used in clinical practice until today,but the classification based on the effect of laser treatment cannot fully meet the update of the current treatment methods.The effectiveness and safety of intravitreal injection of anti-VEGF drugs for improvement of vision has been approved by large clinical trials such as RESOLVE and RIDE/RISE.Intravitreal injection of anti-VEGF drugs has gradually become one of the first-line treatment for diabetic macular edema.To observe the short-term effect of intravitreal Ranibizumab injection in patients with CSME and NCSME.Methods77 patients with non proliferative diabetic macular edema were selected from August 2015 to August 2016 in Affiliated Hospital of Taishan Medical University,all of them carried out the necessary physical examination and comprehensive eye examination,including best corrected visual acuity,intraocular pressure,slit lamp examination of anterior segment,fundus examination,fundus fluorescein angiography(Spectralis HRA+OCT),optical coherence tomography(Spectralis HRA+OCT),color fundus photography(Kowa Nonmyd-DIII Fundus Camera)etc.The cases were divided into CSME group and NCSME group,using SPSS 22 statistical software(IBM,Corp,Version 22.0.0.0)to analysis the best corrected visual acuity and the maximum thickness of macular edema before and after intravitreal injection.ResultsBCVAlogMAR The best corrected visual acuity of 1 weeks and 1 months after treatment in CSME group was significantly different from that before treatment(P<0.05).There was no significant difference in BCVAlogMAR between before and after the 1 week treatment(P>0.05)in the non CSME group,and the difference was statistically significant between after and before the 1 month treatment(P<0.05).The difference of BCVAlogMAR between the CSME group and non CSME group before and after treatment was statistically significant(P<0.05).Maximum thickness of macular edema,maximum thickness of macular edema of In CSME group,after 1 week,1 month of treatment compared with before were statistically significant(P<0.05).In non CSME group,after 1 week,1 month of treatment compared with before were statistically significant(P<0.05).There was no significant difference between the CSME group and the non CSME group before and after treatment in the maximum thickness of macular edema at each time point(P>0.05).The difference between BCVAlogMAR and macular edema was different between the two groups,which indicated that the highest height of macular edema could not reflect the visual acuity.IVR treatment of patients with CSME and NCSME patients has definite curative effect.The adverse reactions and complications In this study did not appear serious ocular adverse reactions,including systemic adverse reactions,vitreous hemorrhage,retinal ischemia,retinal artery occlusion and retinal detachment,and other as previous reported.ConclusionsIntravitreal injection of ranibizumab can alleviate macular edema in patients with CSME and NCSME in the short term,with no significant difference being seen between two groups.The maximum thickness of macular edema cannot truly reflect the visual acuity.